Company Search:
Advanced Search
Sponsored Links
Imexpharm Corp Company Snapshot
Imexpharm Corp operates within the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Imexpharm Corp with three other companies in this sector in Vietnam: Medipharco Pharmaceutical JSC (2016 sales of 844.70 billion Dong [US$37.17 million] ), Hatay Pharmaceutical JSC (1.21 trillion Dong [US$53.04 million] ), and OPC Pharmaceutical JSC (790.41 billion Dong [US$34.78 million] ).

Sales Analysis. During the year ended December of 2016, sales at Imexpharm Corp were 1.01 trillion Dong (US$44.46 million). This is an increase of 4.8% versus 2015, when the company's sales were 964.32 billion Dong. This was the fifth consecutive year of sales increases at Imexpharm Corp (and since 2011, sales have increased a total of 30%).
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Imexpharm Corp
  Stock Performance Chart for Imexpharm Corp
  Stock Data: Recent Stock Performance:
  Current Price (1/19/2018): 67,200
(Figures in Dong)
1 Week 1.8%   13 Weeks 1.5%  
4 Weeks 5.2%   52 Weeks 38.2%  
Imexpharm Corp Key Data:
  Ticker: IMP Country: Vietnam
  Exchanges: Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Medicinals & Botanicals
  2016 Sales 1,010,346,178,305
(Year Ending Jan 2017).
Employees: 605
  Currency: Dong Market Cap: 2,886,801,187,200
  Fiscal Yr Ends: December Shares Outstanding: 42,958,351
  Share Type: Closely Held Shares: 21,346,580
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.